Esrar Kullanımı: Risk Algısı, Ruh Sağlığı Etkileri ve Düzenleyici Politikalar

Yazarlar

Ayşe Taş
https://orcid.org/0000-0001-9909-4411

Referanslar

Breijyeh Z, Jubeh B, Bufo SA, et al. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. Toxins. 2021;13(2):117. doi:10.3390/TOXINS13020117 PubMed PMID: 33562446.

Radwan MM, Chandra S, Gul S, et al. Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules. 2021;26(9):2774. doi:10.3390/MOLECULES26092774 PubMed PMID: 34066753.

Kayaalp SO. Akılcı Tedavi Yönünden Tıbbi Farmakoloji. Ankara: Pelikan Kitabevi; 2024.

Wang Q, Qin Z, Xing X, et al. Prevalence of Cannabis Use around the World: A Systematic Review and Meta-Analysis, 2000–2024. China CDC Wkly. 2024;6(25):597. doi:10.46234/CCDCW2024.116 PubMed PMID: 38933041.

Birleşmiş Milletler. World Drug Report 2026 (19/08/2026 tarihinde https://data.unodc.org/wdr2026?page=62 adresinden ulaşılmıştır).

Miech RA, Patrick ME, O’Malley PM, et al. Monitoring the Future national survey results on drug use, 1975–2025: Overview and detailed results for secondary school students. Michigan: Michigan University Press; 2026.

Han B, Jones CM, Volkow ND, et al. Prevalence of cannabis consumption methods among people with medically recommended and nonmedical cannabis use in the United States. Addiction. 2025;120(5):962–74. doi:10.1111/ADD.16741 PubMed PMID: 39838511.

Oomen PE, Schori D, Tögel-Lins K, et al. Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services. International Journal of Drug Policy. 2022;100:103493. doi:10.1016/J.DRUGPO.2021.103493 PubMed PMID: 34687992.

Andersano B, Cahill TM, Grommes M, et al. Evaluation of illicit drug contaminants in seized cannabis in Arizona and California, 2023-2024. J Forensic Sci. 2026;71(5). doi:10.1111/1556-4029.70365 PubMed PMID: 42186133.

Monti MC, Zeugin J, Koch K, et al. Adulteration of low‐delta‐9‐tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services. Drug Test Anal. 2022;14(6):1026. doi:10.1002/DTA.3220 PubMed PMID: 34997693.

Ferrer RA, Klein WMP. Risk perceptions and health behavior. Curr Opin Psychol. 2015;5:85. doi:10.1016/J.COPSYC.2015.03.012 PubMed PMID: 26258160.

Keyhani S, Steigerwald S, Ishida J, et al. Risks and Benefits of Marijuana Use: A National Survey of U.S. Adults. Ann Intern Med. 2018;169(5):282–90. doi:10.7326/M18-0810 PubMed PMID: 30039154.

Turna J, Balodis I, Van Ameringen M, et al. Attitudes and Beliefs Toward Cannabis Before Recreational Legalization: A Cross-Sectional Study of Community Adults in Ontario. Cannabis Cannabinoid Res. 2022;7(4):526–36.

Goodman S, Hammond D. Perceptions of the health risks of cannabis: estimates from national surveys in Canada and the United States, 2018–2019. Health Educ Res. 2022;37(2):61–78. doi:10.1093/HER/CYAC006 PubMed PMID: 35311986.

Salloum NC, Krauss MJ, Agrawal A, et al. A reciprocal effects analysis of cannabis use and perceptions of risk. Addiction. 2018;113(6):1077–85.

Friese B. “Is Marijuana Even a Drug?” A Qualitative Study of How Teens View Marijuana Use and Why They Use It. J Psychoactive Drugs. 2017;49(3):209–16. doi:10.1080/02791072.2017.1290854 PubMed PMID: 28632075.

Leos-Toro C, Fong GT, Meyer SB, et al. Cannabis health knowledge and risk perceptions among Canadian youth and young adults. Harm Reduction Journal. 2020;17(1):54-. doi:10.1186/S12954-020-00397-W PubMed PMID: 32746859.

Terry-McElrath YM, Pang YC, Patrick ME. Historical change in associations between perceived risk, disapproval, and use of cannabis among young adults ages 19–30, 2011–2022. Addictive Behaviors. 2025;160:108185. doi:10.1016/J.ADDBEH.2024.108185 PubMed PMID: 39388852.

Bondarenko AI. Cannabinoids and Cardiovascular System. Adv Exp Med Biol. 2019;1162:63–87. doi:10.1007/978-3-030-21737-2_5/SAVE-RESEARCH PubMed PMID: 31332735.

Seffah KD, Kumar M, Naveen N, et al. To Weed or Not to Weed: A Systematic Review Exploring the Potential for Cannabis Use in Cardiovascular Disease, Mental Health and Pain Management. Cureus. 2023;15(6). doi:10.7759/CUREUS.40606 PubMed PMID: 37476127.

Storck W, Elbaz M, Vindis C, et al. Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart. 2025;111(22):1047–56. doi:10.1136/HEARTJNL-2024-325429 PubMed PMID: 40527600.

Muheriwa-Matemba SR, Baral A, Abdshah A, et al. Cardiovascular and Respiratory Effects of Cannabis Use by Route of Administration: A Systematic Review. Subst Use Misuse. 2024;59(9):1331–51. doi:10.1080/10826084.2024.2341317 PubMed PMID: 38644600.

Martinasek MP, McGrogan JB, Maysonet A. A Systematic Review of the Respiratory Effects of Inhalational Marijuana. Respir Care. 2016;61(11):1543–51. doi:10.4187/RESPCARE.04846 PubMed PMID: 27507173.

Malvi A, Khatib MN, Balaraman AK, et al. Cannabis consumption and risk of asthma: a systematic review and meta-analysis. BMC Pulm Med. 2025;25(1). doi:10.1186/S12890-025-03516-0 PubMed PMID: 39881272.

Vásconez-González J, Delgado-Moreira K, López-Molina B, et al. Effects of Smoking Marijuana on the Respiratory System: A Systematic Review. Subst Abus. 2023;44(3):249–60. doi:10.1177/08897077231186228 PubMed PMID: 37728136.

Georgakopoulou VE, Andreikos DA, Zhu W, et al. Cannabis use and its impact on respiratory physiology and lung cancer risk: Mechanistic and epidemiological insights (Review). Biomed Rep. 2025;23(5):1–17. doi:10.3892/BR.2025.2058/HTML

Richter JS, Quenardelle V, Rouyer O, et al. A systematic review of the complex effects of cannabinoids on cerebral and peripheral circulation in animal models. Front Physiol. 2018;9(MAY):363348. doi:10.3389/FPHYS.2018.00622/FULL

Archie SR, Cucullo L. Harmful effects of smoking cannabis: A cerebrovascular and neurological perspective. Front Pharmacol. 2019;10:491828. doi:10.3389/FPHAR.2019.01481/FULL

Humayun M, Suarez JI, Shah VA. Neurological Complications of Cannabinoids. Semin Neurol. 2024;44(4):430–40. doi:10.1055/S-0044-1787570/ID/JR20240028-19/BIB PubMed PMID: 38914126.

Hayes S, Delker E, Bandoli G. The prevalence of cannabis use reported among pregnant individuals in the United States is increasing, 2002–2020. Journal of Perinatology. 2022;43(3):387–9. doi:10.1038/s41372-022-01550-y PubMed PMID: 36310241.

Singh S, Filion KB, Abenhaim HA, et al. Prevalence and outcomes of prenatal recreational cannabis use in high-income countries: a scoping review. BJOG. 2020;127(1):8–16.

Corsi DJ, Donelle J, Sucha E, et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nature Medicine. 2020;26(10):1536–40. doi:10.1038/s41591-020-1002-5 PubMed PMID: 32778828.

Tadesse AW, Dachew BA, Ayano G, et al. Prenatal cannabis use and the risk of attention deficit hyperactivity disorder and autism spectrum disorder in offspring: A systematic review and meta-analysis. J Psychiatr Res. 2024;171:142–51. doi:10.1016/J.JPSYCHIRES.2024.01.045 PubMed PMID: 38281464.

Cajachagua-Torres KN, Boer OD, et al. The association of preconception and prenatal cannabis and tobacco exposure with autism symptoms in offspring: A population-based longitudinal study. Neurotoxicol Teratol. 2025;112:107561. doi:10.1016/J.NTT.2025.107561 PubMed PMID: 41016606.

Gerede A, Stavros S, Chatzakis C, et al. Cannabis Use during Pregnancy: An Update. Medicina. 2024;60(10):1691. doi:10.3390/MEDICINA60101691 PubMed PMID: 39459478.

Cohen K, Weinstein AM. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Front Public Health. 2018;6:349132. doi:10.3389/FPUBH.2018.00162/FULL

Hasan A, von Keller R, Friemel CM, et al. Cannabis use and psychosis: a review of reviews. Eur Arch Psychiatry Clin Neurosci. 2020;270(4):403–12. doi:10.1007/S00406-019-01068-Z/FIGURES/1 PubMed PMID: 31563981.

Linscott RJ, Van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med. 2013;43(6):1133–49. doi:10.1017/S0033291712001626 PubMed PMID: 22850401.

Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med. 2016;46(4):673–81. doi:10.1017/S0033291715002329 PubMed PMID: 26568030.

Koskinen J, Löhönen J, Koponen H. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36(6):1115–30. doi:10.1093/SCHBUL/SBP031 PubMed PMID: 19386576.

Myles H, Myles N, Large M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust N Z J Psychiatry. 2016;50(3):208–19. doi:10.1177/0004867415599846 PubMed PMID: 26286531.

Marconi A, Di Forti M, Lewis CM. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016;42(5):1262–9. doi:10.1093/SCHBUL/SBW003 PubMed PMID: 26884547.

Large M, Sharma S, Compton MT, et al. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61. doi:10.1001/ARCHGENPSYCHIATRY.2011.5 PubMed PMID: 21300939.

Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28. doi:10.1016/S0140-6736(07)61162-3 PubMed PMID: 17662880.

Zammit S, Moore THM, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193(5):357–63. doi:10.1192/BJP.BP.107.046375 PubMed PMID: 18978312.

Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry. 2016;3(3):215–25. doi:10.1016/S2215-0366(15)00363-6 PubMed PMID: 26777297.

Hinckley JD, Conner BT, Mauch R, et al. A Systematic Review: Investigating Biomarkers of Anhedonia and Amotivation in Depression and Cannabis Use. JAACAP Open. 2025;3(3):379–405. doi:10.1016/j.jaacop.2024.08.005. doi:10.1016/j.jaacop.2024.08.005

Onaemo VN, Fawehinmi TO, D’Arcy C. Comorbid Cannabis Use Disorder with Major Depression and Generalized Anxiety Disorder: A Systematic Review with Meta-analysis of Nationally Representative Epidemiological Surveys. J Affect Disord. 2021;281:467–75. doi:10.1016/j.jad.2020.12.043 PubMed PMID: 33360749.

Churchill V, Chubb CS, Popova L, et al. The association between cannabis and depression: an updated Systematic Review and Meta-analysis. Psychol Med. 2025;55. doi:10.1017/S0033291724003143 PubMed PMID: 39936870.

Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Soc Sci Med. 2019;233:181–92. doi:10.1016/j.socscimed.2019.06.005 PubMed PMID: 31207470.

Lev-Ran S, Roerecke M, Le Foll B, et al. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810. doi:10.1017/S0033291713001438 PubMed PMID: 23795762.

Hosseini S, Oremus M. The Effect of Age of Initiation of Cannabis Use on Psychosis, Depression, and Anxiety among Youth under 25 Years. Can J Psychiatry. 2019;64(5):304–12. doi:10.1177/0706743718809339 PubMed PMID: 30373388.

Sorkhou M, Dent EL, George TP. Cannabis use and mood disorders: a systematic review. Front Public Health. 2024;12. doi:10.3389/FPUBH.2024.1346207 PubMed PMID: 38655516.

Rittiphairoj T, Leslie L, Oberste JP, et al. High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. Ann Intern Med. 2025;178(10):1429–40. doi:10.7326/ANNALS-24-03819 PubMed PMID: 40854216.

Lowe DJE, Sorkhou M, George TP. Cannabis use in adolescents and anxiety symptoms and disorders: a systematic review and meta-analysis. Am J Drug Alcohol Abuse. 2024;50(2):150–61. doi:10.1080/00952990.2023.2299922 PubMed PMID: 38285048.

Single A, Bilevicius E, Ho V, et al. Cannabis use and social anxiety in young adulthood: A meta-analysis. Addictive Behaviors. 2022;129. doi:10.1016/j.addbeh.2022.107275 PubMed PMID: 35184002.

Sharpe L, Sinclair J, Kramer A, et al. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18(1). doi:10.1186/S12967-020-02518-2 PubMed PMID: 33008420.

Mulligan LD, Varese F, Harris K, et al. Cannabis use and suicide in people with a diagnosis of schizophrenia: a systematic review and meta-analysis of longitudinal, case control, and cross-sectional studies. Psychol Med. 2025;55. doi:10.1017/S0033291725000236 PubMed PMID: 40059733.

Shamabadi A, Ahmadzade A, Pirahesh K, et al. Suicidality risk after using cannabis and cannabinoids: An umbrella review. Dialogues Clin Neurosci. 2023;25(1):50–63. doi:10.1080/19585969.2023.2231466 PubMed PMID: 37427882.

Bartoli F, Crocamo C, Carrà G. Cannabis use disorder and suicide attempts in bipolar disorder: A meta-analysis. Neurosci Biobehav Rev. 2019;103:14–20. doi:10.1016/j.neubiorev.2019.05.017 PubMed PMID: 31121199.

Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. J Affect Disord. 2016;195:63–74. doi:10.1016/j.jad.2016.02.007 PubMed PMID: 26872332.

Ricci V, Sarni A, Barresi M, et al. Cannabis and suicide risk in first-episode psychosis: Mechanisms, interactions, and intervention strategies. Asian J Psychiatr. 2025;110. doi:10.1016/j.ajp.2025.104624 PubMed PMID: 40651081.

Fresán A, Dionisio-García DM, González-Castro TB, et al. Cannabis smoking increases the risk of suicide ideation and suicide attempt in young individuals of 11–21 years: A systematic review and meta-analysis. J Psychiatr Res. 2022;153:90–8. doi:10.1016/j.jpsychires.2022.06.053 PubMed PMID: 35810604.

Dünya Sağlık Örgütü. Alcohol, Drugs and Addictive Behaviours. (26/08/2026 tarihinde https://www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis adresinden ulaşılmıştır).

Köroğlu E. DSM-5-TR Ruhsal Bozuklukların Tanısal ve Sayımsal El Kitabı: Yeniden Gözden Geçirilmiş Beşinci Baskı. Ankara: Esenkal Yayıncılık; 2025.

Budney AJ, Borodovsky JT, Knapp AA. Clinical Manifestations of Cannabis Use Disorder. Cannabis Use Disorders. 2019;85–91. doi:10.1007/978-3-319-90365-1_10

Zehra A, Burns J, Liu CK, et al. Cannabis Addiction and the Brain: a Review. Journal of Neuroimmune Pharmacology. 2018;13(4):438. doi:10.1007/S11481-018-9782-9 PubMed PMID: 29556883.

Boyle EB, Hurd YL, Teutsch SM. Overview of Cannabis Policy. In: National Academies of Sciences E and MH and MDB on PH and PHPC on the PHC of C in the CPL (eds). Cannabis Policy Impacts Public Health and Health Equity. 2024.

Hall W, Lynskey M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry. 2020;19(2):179–86. doi:10.1002/WPS.20735;SUBPAGE:STRING:FULL PubMed PMID: 32394566.

Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. Am J Drug Alcohol Abuse. 2019;45(6):644–63. doi:10.1080/00952990.2019.1669626 PubMed PMID: 31603710.

Farrelly KN, Wardell JD, Marsden E, et al. The Impact of Recreational Cannabis Legalization on Cannabis Use and Associated Outcomes: A Systematic Review. Subst Abuse. 2023;17.

Yayınlanan

18 Kasım 2026

Lisans

Lisans